In 2000, at Memorial Sloan Kettering Cancer Center, Sheinberg et al. [24] studied the in vitro and in vivo use of a novel α-particle emitting monoclonal antibody (J591) targeting the external domain of PSMA, which showed a significant prostatic-specific antigen (PSA) reduction and higher tumor-free survival in mice. Here, KLK3 is linked to neoplasm.